微创良性前肠手术与术后长期持续阿片类药物使用无关:IBM MarketScan数据库分析
本研究基于IBM MarketScan商业保险数据库,纳入2010至2018年接受腹腔镜胃底折叠术、食管裂孔疝修补术或Heller肌切开术的阿片类药物初治成人患者共17,530例,评估术后持续阿片类药物使用情况。结果显示仅0.4%(65例)患者在术后365天达到持续使用标准,风险低于1%,支持当前限制普外科术后阿片类药物处方数量的指南。
要点
- 微创良性前肠手术后持续阿片类药物使用风险低于1%。
- 仅约半数阿片初治患者围术期配取过阿片类药物。
- 较低查尔森合并症指数及精神疾病或物质使用障碍史对持续使用有统计学但非临床显著的保护效应。
核心结论
- 微创良性前肠手术的阿片初治患者进展为持续术后阿片类药物使用的风险低于1%。
- 研究结果支持当前限制普外科术后阿片类药物处方片数的指南。
研究设计与样本
- 基于IBM MarketScan商业理赔与 encounters 数据库的回顾性队列分析,纳入2010至2018年接受腹腔镜胃底折叠术、食管裂孔疝修补术或Heller肌切开术的阿片初治成人患者共17,530例。
主要发现
- 共17,530例患者纳入分析,其中胃底折叠术6,895例、食管裂孔疝修补术9,235例、Heller肌切开术1,400例。
- 9,652例患者在围术期至少配取过一次阿片类药物处方。
- 65例(0.4%)患者在术后365天随访时存在持续术后阿片类药物使用。
- 较低的查尔森合并症指数评分及精神疾病或物质使用障碍史对术后365天持续阿片类药物使用风险具有统计学显著但非临床显著的保护效应。
关键数值与推荐
- 持续术后阿片类药物使用定义为随访365天时阿片类药物处方覆盖天数比例至少33%。
临床怎么用
- 对于接受微创良性前肠手术的阿片初治患者,术后进展为持续阿片类药物使用的风险较低,可参考当前限制普外科术后阿片类药物处方数量的指南。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unknown if opioid naïve patients who undergo minimally invasive, benign foregut operations are at risk for progressing to persistent postoperative opioid use. The purpose of our study was to determine if opioid naïve patients who undergo minimally invasive, benign foregut operations progress to persistent postoperative opioid use and to identify any patient- and surgery-specific factors associated with persistent postoperative opioid use. METHODS: Opioid-naïve, adult patients who underwent laparoscopic fundoplication, hiatal hernia repair, or Heller myotomy from 2010 to 2018 were identified within the IBM® MarketScan® Commercial Claims and Encounters Database. Daily drug logs of the preoperative and postoperative period were evaluated to assess for changes in drug use patters. The primary outcome of interest was persistent postoperative opioid use, defined as at least 33% of the proportion of days covered by opioid prescriptions at 365-day follow-up. Patient demographic information and clinical risk factors for persistent postoperative opioid use at 365 days postoperatively were estimated using log-binomial regression. RESULTS: A total of 17,530 patients met inclusion criteria; 6895 underwent fundoplication, 9235 underwent hiatal hernia repair, and 1400 underwent Heller myotomy. 9652 patients had at least one opioid prescription filled in the perioperative period. Sixty-five patients (0.4%) were found to have persistent postoperative opioid use at 365 days postoperatively. Lower Charlson comorbidity index scores and a history of mental illness or substance use disorder had a statistically but not clinically significant protective effect on the risk of persistent postoperative opioid use at 365 days postoperatively. CONCLUSIONS: Only half of opioid naïve patients undergoing minimally invasive, benign foregut operations filled an opioid prescription postoperatively. The risk of progression to persistent postoperative opioid use was less than 1%. These findings support the current guidelines that limit the number of opioid pills prescribed following general surgery operations.
引用
- Haskins IN, Duchesneau ED, Agala CB, et al. Minimally invasive, benign foregut surgery is not associated with long-term, persistent opioid use postoperatively: an analysis of the IBM® MarketScan® database. Surg Endosc. 2022. PMID: 35229211. doi:10.1007/s00464-022-09123-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。